Q-omics provides the consensus-scored KCNJ15 profile across patient tissues and cancer cell-line models. KCNJ15 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KCNJ15 is differentially expressed in 14, with the highest sampling consensus in KICH. Additionally, KCNJ15 RNA expression shows 19,507 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, KICH, and LSCC as cancer lineages where KCNJ15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KCNJ15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KCNJ15 survival associations across molecular data types. KCNJ15 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KCNJ15 RNA expression–survival associations across cancer types. High KCNJ15 expression shows unfavorable associations in STAD, HNSC and UVM, but favorable associations in KIRC, BLCA and KIRP. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KCNJ15 RNA expression.
This table summarizes KCNJ15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for KCNJ15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KCNJ15 shows lower tumor expression in KICH, LUAD, KIRC, LUSC and KIRP and higher tumor expression in HNSC. The KICH box plot shows higher KCNJ15 RNA expression in normal versus tumor tissue (log2 FC = −4.475, t-test p < 0.001).
This table shows molecular features associated with KCNJ15 in patient tissues and cancer cell lines. In patient samples, KCNJ15 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, KCNJ15 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BONE.
